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IODO-NONOXYNOL-9-DERIVATIVES AND 
METHODS FOR THEIR USE 
TECHNICAL FIELD 
The present invention relates to mono- and di-iodinated 
nonoxynol-9-derivatives and methods for their use. 
BACKGROUND ART 
Nonionic surfactants are a preferred class of active agents 
for use in spermicidal formulations. For example, the non 
ionic surfactant nonoxynol-9 is a component in many com 
mercially available spermicidal formulations. Spermicidal 
formulations are administered in the vaginal cavity for their 
local activity against human spermatoZoa. It has been theo 
riZed that spermicidal agents exert their activity by inserting 
a hydrophobic moiety into the spermatoZoan cell membrane. 
Upon insertion, the spermicidal agents disrupt the integrity 
of the cell membrane. This leads to an osmotic imbalance in 
the cell and, ultimately, cell lysis, thereby preventing sperm 
from fertiliZing the egg and impeding conception. 
Mixed experimental evidence exists as to Whether non 
ionic surfactants used in spermicides kill human immuno 
de?ciency virus (HIV). In vitro experiments reveal that 
nonoxynol-9 inactivates HIV-1 completely. The inactivation 
may be through a mechanism similar to that proposed for the 
reduction of sperm motility. The hydrophobic portion of the 
nonoxynol-9 molecule may associate With hydrophobic 
fragments on the surface of the HIV virion leading to the 
derangement of the viral envelope and inactivation. The 
hydrophobic moieties of the virion include constituent 
lipids, sterols and proteins of the host cell membrane from 
Which the viral envelope stems in addition to viral proteins. 
Nonoxynol-9 suffers from a number of draWbacks. For 
example, in vivo clinical trials of products containing 
nonoxynol-9 do not shoW clear evidence of protection 
against HIV infection. Certain studies indicated that HIV 
infection rates Were essentially equal When a population of 
Women used vaginal contraceptives containing nonoxynol-9 
or a placebo. Furthermore, vaginal irritation appears to 
increase With increased dose of nonoxynol-9. 
A need exists for compounds Which are more effective at 
loWer doses, and Which can achieve equal or greater con 
traceptive and anti-HIV ef?cacy With less irritation. 
DISCLOSURE OF THE INVENTION 
An advantage of the present invention is the provision of 
compounds Which are effective to prevent conception. 
Another advantage of the present invention is the provi 
sion of compounds Which are effective to reduce or prevent 
transmission of sexually transmitted diseases. 
Additional advantages of the present invention Will be set 
forth in part in the description Which folloWs and in part Will 
become apparent to those having ordinary skill in the art 
upon examination of the folloWing or may be learned from 
the practice of the present invention. The advantages of the 
present invention may be realiZed and obtained as particu 
larly pointed out in the appended claims. 
According to the present invention, the foregoing and 
other advantages are achieved in part by a compound of the 
formula: 
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Wherein R is a carbon atom containing moiety having at least 
6 carbon atoms, Q is H or I, and n=1—25. 
Another aspect of the present invention is a pharmaceu 
tical composition comprising a compound of formula (I), 
and a pharmaceutically acceptable carrier. 
A further aspect of the present invention is a method for 
preventing conception, the method comprising the step of 
administering an effective amount of a compound of formula 
(I). 
Yet another aspect of the present invention is a method for 
reducing or preventing transmission of a sexually transmit 
ted disease, the method comprising the step of administering 
an effective amount of a compound of formula 
One more aspect of the present invention relates to plastic 
and paper products coated With compounds of formula 
An additional aspect of the present invention is a process 
for preparing a compound of formula (I), the process com 
prising the steps of reacting thallium tri?uoroacetate With a 
compound of formula: 
Wherein R and n are as de?ned above to form an electro 
philic thallium intermediate, and iodinating the intermedi 
ate. 
Additional advantages of the present invention Will 
become readily apparent to those skilled in this art from the 
folloWing detailed description, Wherein only the preferred 
embodiment of the present invention is shoWn and 
described, simply by Way of illustration of the best mode 
contemplated for carrying out the present invention. As Will 
be realiZed, the present invention is capable of other and 
different embodiments, and its several details are capable of 
modi?cations in various obvious respects, all Without 
departing from the present invention. Accordingly, the draW 
ings and description are to be regarded as illustrative in 
nature, and not as restrictive. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 illustrates an abbreviated synthetic pathWay for 
mono-iodination of nonoxynol-9 according to the present 
invention. 
FIG. 2 illustrates a reverse-phase HPLC chromatogram of 
mono-iodinated nonoxynol-9 reaction product (Waters C-18 
analytical column, mobile phase=methanol:Water (80:20) 
obtained by the present invention. 
FIG. 3 illustrates the aromatic region of H-NMR of 
mono-iodinated nonoxynol-9 (in CDCl3) according to the 
present invention. 
FIG. 4 illustrates the aromatic region of H-NMR of 
nonoxynol-9 (in CDCl3). 
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FIG. 5 illustrates an abbreviated synthetic pathway for 
di-iodination of nonoxynol-9 according to the present inven 
tion. 
FIG. 6 illustrates the aromatic region of H-NMR of 
di-iodinated nonoxynol-9 (in CDCl3) according to the 
present invention. 
FIG. 7 illustrates a FAB mass spectral analysis for a 
collected nonoxynol-9 (oligomer 7, n=7) fraction. 
FIG. 8 illustrates a FAB mass spectral analysis for a 
collected mono-iodinated nonoxynol-9 (oligomer 7, n=7) 
fraction according to the present invention. 
FIG. 9 illustrates a FAB mass spectral analysis for 
di-iodinated nonoxynol-9 (oligomers 1—17, n=1—17). 
DESCRIPTION OF THE INVENTION 
The present invention provides compounds of the for 
mula: 
Wherein R is a carbon atom containing moiety having at least 
6 carbon atoms, Q is H or I and n=1—25. 
The compounds of the present invention may be indi 
vidual oligomers or mixtures thereof. In other Words, the 
compounds of the present invention can be obtained from a 
starting material Which is a multicomponent mixture of 
different oligomers having ethylene oxide chains With dif 
ferent lengths, represented by “n” Which denotes the number 
of ethylene oxide units. The iodinated compounds can be 
also obtained from their respective oligomers of, for 
example, nonoxynol-9 by utiliZing the iodination reaction 
described herein. 
R can be any carbon atom containing moiety having at 
least 6 carbon atoms. Examples of carbon atom containing 
moieties include unsubstituted or substituted straight or 
branched chain alkyl groups such as octyl and nonyl; 
unsubstituted phenyl, biphenyl and naphthyl groups; substi 
tuted and unsubstituted aryl groups; polycyclic groups, 
alicyclic groups, etc. 
The compounds may be mono-iodinated (Q is H) or 
di-iodinated (Q is I). The iodine may be, for example, 
123-iodine, 125-iodine, 127-iodine and 131-iodine. 
n may range from 1—25, such as, from 4 to 15 and more 
particularly, from 6—8. When n is 1—6, the compounds are 
typically Water-insoluble. When n is 17—25, the compounds 
are typically Water-soluble. 
The compounds for use in the present invention can be 
administered as a pharmaceutical composition. The pharma 
ceutical compositions of the present invention comprise at 
least one compound of formula (I), i.e., at least one active 
agent, in combination With a pharmaceutical carrier or 
excipients. 
The pharmaceutical compositions can be in any form 
suitable for oral administration, or for topical administration 
to the vagina. Suitable forms include tablets (including 
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loZenges and granules), dragees, capsules, pills, sponges, 
creams, liquids, douches, gels, jellies, aerosol foams, 
impregnated tampons, ovules, controlled delivery device or 
as a lubricant on, for example, a condom or a cap diaphragm. 
“Pharmaceutical composition” means physically discrete 
coherent portions suitable for medical administration. 
“Pharmaceutical composition in dosage unit form” means 
physically discrete coherent units suitable for medical 
administration, each containing a daily dose or a multiple 
(up to four times) or a sub-multiple (doWn to a fortieth) of 
a daily dose of the active agent of the invention in associa 
tion With a carrier and/or enclosed Within an envelope. 
Whether the composition contains a daily dose, or for 
example, a half, a third or a quarter of a daily dose Will 
depend on Whether the pharmaceutical composition is to be 
administered once or, for example, tWice, three times or four 
times a day, respectively. 
Advantageously, the compositions are formulated as dos 
age units, each unit being adapted to supply a ?xed dose of 
active ingredients. Tablets and capsules are examples of 
preferred dosage forms according to the invention. It is only 
necessary that the active ingredient constitute an effective 
amount, i.e., such that a suitable effective dosage Will be 
consistent With the dosage form employed in single or 
multiple unit doses. The exact individual dosages, as Well as 
daily dosages, are determined according to standard medical 
principles under the direction of a physician. 
The active agents can also be administered as 
suspensions, solutions and emulsions of the active com 
pound in aqueous or non-aqueous diluents, syrups, granu 
lates or poWders. Diluents that can be used in pharmaceu 
tical compositions (e.g., granulates) containing the active 
compound adapted to be formed into tablets, dragees, cap 
sules and pills include the folloWing: (a) ?llers and 
extenders, e.g., starch, sugars, mannitol and silicic acid; (b) 
binding agents, e.g., carboxymethyl cellulose and other 
cellulose derivatives, alginates, gelatine and polyvinyl pyr 
rolidone; (c) moisturiZing agents, e.g., glycerol; (d) disinte 
grating agents, e.g., agar-agar, calcium carbonate and 
sodium bicarbonate; (e) agents for retarding dissolution, 
e.g., paraf?n; resorption accelerators, e.g., quaternary 
ammonium compounds; (g) surface active agents, e.g., cetyl 
alcohol, glycerol monostearate; (h) adsorptive carriers, e.g., 
kaolin and bentonite; lubricants, e.g., talc, calcium and 
magnesium stearate and solid polyethylene glycols. 
The tablets, capsules and pills comprising the active agent 
can have the customary coatings, envelopes and protective 
matrices, Which may contain opaci?ers. They can be so 
constituted that they release the active ingredient only or 
preferably in a particular part of the intestinal tract, possibly 
over a period of time. The coatings, envelopes and protective 
matrices may be made, for example, from polymeric sub 
stances or Waxes. 
The active ingredient can also be made up in microen 
capsulated form together, With one or several of the above 
mentioned diluents. 
The pharmaceutical compositions Which are solutions and 
emulsions can, for example, contain the customary diluents, 
such as dissolving agents and emulsi?ers. Speci?c non 
limiting examples of such diluents are Water, ethyl alcohol, 
isopropyl alcohol, ethyl carbonate, ethyl acetate, benZyl 
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alcohol, benZyl benZoate, propylene glycol, 1,3-butylene 
glycol, dimethylformamide, oils (for example, ground nut 
oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene gly 
cols and fatty acid esters of sorbitol or mixtures thereof. 
The pharmaceutical compositions Will generally contain 
from about 0.0001 to 90 Wt. %, preferably about 0.01 to 10 
Wt. % of the active ingredient by Weight of the total 
composition. In addition to the active agent, the pharma 
ceutical compositions and medicaments can also contain 
other pharmaceutically active compounds. 
Any diluent in the pharmaceutical compositions of the 
present invention may be any of those mentioned above in 
relation to the pharmaceutical compositions. 
In addition, the present invention relates to synergistic 
pharmaceutical compositions Wherein the active agent is 
complexed With polyvinylpyrrolidone (PVP). As a result of 
the synergy betWeen the PVP and the compounds of formula 
(I), solutions With small concentrations of the inventive 
compounds can be used, resulting in reduced vaginal irrita 
tion. 
The dosage rate, e.g., about 0.04 to about 100 mg/kg of 
body Weight, such as about 0.01 to about 1 mg/kg Will be a 
function of the nature and body Weight of the human to be 
treated, the individual reaction of this subject to the 
treatment, type of formulation in Which the active ingredient 
is administered, the mode in Which the administration is 
carried out and the point in the progress of the disease or 
interval at Which it is to be administered. Thus, it may in 
some case suf?ce to use less than a minimum dosage rate, 
While other cases an upper limit must be exceeded to achieve 
the desired results. Where larger amounts are administered, 
it may be advisable to divide these into several individual 
administrations over the course of the day. 
Where it is desired to administer the compound vaginally, 
a vaginal suppository may be prepared by mixing the active 
constituents With at least one polyethylene glycol, the glycol 
or mixture of glycols having a melting point at or beloW 
body temperature. To facilitate the ef?cient dispersion of the 
active ingredient in the vagina, the suppository may also 
contain foam producing substances, such as sodium bicar 
bonate and sodium phosphate, and, to assure long duration 
of the foam, a foam stabiliZing agent, such as sodium lauryl 
sulfate can be used. 
Alternatively, a sponge may be prepared by absorbing the 
active constituents into a biocompatible, bioinsoluble, non 
toxic sponge-like soft polymer Suitable polymers for this 
use are Well knoWn in the art, and include, for example, 
2-hydroxyethylmethacrylate. 
Acream according to this invention may contain a hydro 
carbon base, such as White petrolatum, a solvent, such as 
glycerin or propylene glycol, and an emulsi?er, such as cetyl 
alcohol. 
Inventive formulations can be administered topically to 
the vaginal cavity for their local activity against human 
spermatoZoa. 
The present invention further relates to a method for 
preventing conception, the method comprising the step of 
administering an effective amount of a compound of formula 
(I). 
By “prevention of conception” it is meant that a viable 
Zygote cannot be formed. 
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In addition, the present invention relates to a method for 
reducing or preventing transmission of a sexually transmit 
ted disease, the method comprising the step of administering 
an effective amount of a compound of formula In one 
embodiment, the compound is administered topically to the 
vaginal cavity. 
By “sexually transmitted disease”, it is meant any com 
municable disease transmitted by sexual intercourse or geni 
tal contact, for example, HIV, gonorrhea and syphilis. 
In the previous descriptions, numerous speci?c details are 
set forth, such as speci?c materials, structures, chemicals, 
processes, etc., in order to provide a thorough understanding 
of the present invention. HoWever, the present invention can 
be practiced Without resorting to the details speci?cally set 
forth. In other instances, Well knoWn processing structures 
have not been described in detail in order not to unneces 
sarily obscure the present invention. 
EXAMPLE 1 
Synthesis of Mono-iodinated Nonoxynol-9 
This example describes the synthesis of mono-iodinated 
Nonoxynol-9. 
Mono-iodinated nonoxynol-9 (IN-9) Was prepared 
through a series of chemical reactions using nonoxynol-9 
(N-9) (Igepal CO-630) (Rhone-Poulenc, lot. SP6C057657) 
as the starting material. Thallium tri?uoroacetate (TTFA) 
(Aldrich Chemical Co., lot 02601KQ) (20.60 gm, 37.9 
mmol) Was solubiliZed in tri?uoroacetic acid (TFA) (Fisher 
Biotech, lot. 955483) (50 mL, 74 gm) to yield a light broWn 
solution. N-9 (20.23 gm, 32.84 mmol) Was added to a 125 
mL Erlenmeyer ?ask equipped With a magnetic stir bar. The 
TTFA-TFA solution Was added dropWise over 10 minutes 
into the Erlenmeyer ?ask containing N-9 While stirring and 
keeping the reaction ?ask at room temperature and pressure. 
At the onset of the addition, the solution contained in the 
Erlenmeyer ?ask Was light broWn in color and gave Way to 
a dark broWn color over time. The solution Was stirred for an 
additional 20 minutes to alloW the thallium species to react 
With N-9 completely. 
Potassium iodide (KI) (Aldrich Chemical Co., lot 
03330PN) (40.78 gm, 245.6 mmol) Was dissolved in 120 mL 
of deioniZed Water and added dropWise to the ?ask contain 
ing the N-9 solution over a period of ?ve minutes While 
stirring. During the addition of the KI solution, a dull 
yelloW, globular precipitate Was formed in copious amounts. 
Thereafter, sodium metabisul?te (Aldrich Chemical Co., lot. 
11824HG) (5.01 gm, 26.35 mmol) Was added to the ?ask 
and alloWed to stir for 10 minutes. A 10 M NaOH solution 
(Aldrich Chemical Co., lot. 06928T2) Was added until the 
solution Was neutraliZed and brought to pH=8. Near the 
neutraliZation point, the formed precipitate attained a ?ne, 
granular appearance and Was bright yelloW in color. At this 
point, the bright yelloW precipitate Was removed by suction 
?ltration using a Buechner funnel, No. 1 Whatman ?lter 
paper and an Erlenmeyer ?lter ?ask. 
The aqueous ?ltrate had a golden broWn appearance and 
Was Washed With chloroform (Fisher Chemical Co., lot. 
970035) (3 portions, 150 mL total) in a 250 mL separatory 
funnel to extract the product. The collected chloroform 
Washings Were Washed With deioniZed Water (2 portions, 
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100 mL total) in a clean 250 mL separatory funnel. The 
Washed chloroform Was transferred to a 200 mL Erlenmeyer 
?ask and stirred for 4 hours With magnesium sulfate mono 
hydrate (Aldrich Chemical Co., lot. 43418-3) to remove any 
residual Water. A sintered glass funnel (10—15 pm pore siZe) 
Was used to remove the magnesium sulfate from the solu 
tion. The chloroform layer Was transferred to a 250 mL 
round bottom ?ask to remove the solvent by reduced pres 
sure at 60° C. leaving 22.74 gm (93.1% Weight recovery) of 
a yelloW, viscous liquid. The iodine atom in IN-9 Was 
expected to add at the ortho position of the aromatic ring 
relative to the polyethylene oxide side chain. The general 
arrangement of the synthesis of the mono-iodinated N-9 
(IN-9) is shoWn in FIG. 1. 
Analysis of the resulting product indicated that virtually 
all of the N-9 Was converted to the mono-iodinated species. 
The analysis of the reaction product Was conducted by a 
reverse phase HPLC assay using a C-18 column (Waters 
Bondapak, 3.9><300 mm, #P11061B40) With methanol/Water 
(80:20) as a mobile phase. An ultraviolet (UV) detector set 
at 280 nm alloWed for the detection of the product and 
starting material. N-9 Was undetectable in the product 
obtained using the above HPLC procedure and only one 
peak, shoWn in FIG. 2, that of the mono-iodinated product, 
Was observed. A H-NMR spectra, in CDCl3, alloWed for the 
quanti?cation of protons located on the aromatic ring. As 
shoWn in FIG. 3, three peaks Were detected in the aromatic 
region of the spectra from 6.7—7.5 ppm for IN-9 indicating 
three chemically distinct protons on the ring. The appear 
ance of three distinct protons veri?ed that an iodide atom 
had replaced a proton on the aromatic ring of N-9. As shoWn 
in FIG. 4, in this same region of the spectra, the spectra of 
N-9 revealed only tWo distinct protons. These spectra Were 
consistent With the expected structural formulas of the 
compounds. 
EXAMPLE 2 
Synthesis of Di-iodinated Nonoxynol-9 
This example describes the synthesis of di-iodinated 
Nonoxynol-9. 
Di-iodinated Nonoxynol-9 (Di-IN-9) Was prepared using 
chemical steps similar to those rendered to produce the 
mono-iodinated species. In this synthetic procedure, the 
folloWing changes Were incorporated. The molar ratio of 
TTFA to N-9 Was altered to alloW for the additions of tWo 
TTFA molecules per aromatic ring of N-9 (2.16 moles of 
TTFA to 1 mole of N-9). The dropWise addition of the 
TTFA/TFA solution to N-9 Was conducted in a 100 mL 
round bottom ?ask With stirring. Upon the completion of the 
addition of the TTFA/TFA solution to N-9, the mixture Was 
heated to 60° C. With a condenser in place for 24 hours While 
stirring. The amount of sodium metabisul?te Was increased 
(10.10 gm, 53.13 mmol) in order to compensate for the 
increased amount of TTFA in the reaction. OtherWise, the 
chemical steps and the molar ratios used Were precisely the 
same as those performed in the synthesis of the mono 
iodinated species, described above. The general arrangement 
of the synthesis of di-iodinated N-9 (Di-IN-9) is shoWn in 
FIG. 5. 
Analysis of the Di-IN-9 product, using the same reverse 
HPLC procedure mentioned previously, revealed a mixture 
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of approximately 60% Di-IN-9 and 40% of IN-9. Both the 
iodide atoms in the Di-IN-9 Were expected to add at the 
ortho positions of the aromatic ring relative to the polyeth 
ylene oxide side chain. The Di-In-9 and IN-9 species Were 
separated by HPLC using a preparative C-18 column 
(Waters p-Bondapak, 19><300 mm, # M6179101) and a 
mobile phase of 80% MeOH and 20% H2O. As shoWn in 
FIG. 6, the H-NMR of the Di-IN-9 derivative revealed only 
one chemically distinct proton in the aromatic region at 7.6 
ppm, Which is consistent With the expected structural for 
mula. 
EXAMPLE 3 
This example shoWs characteriZation data, including HLB 
values, retention times on the normal HPLC system and the 
log1O of their partition coef?cients, for the inventive oligo 
mers. 
A simple method of comparing structurally similar sur 
factants can be performed by calculating the hydrophilic 
lipophilic balance (HLB) of the compounds. This calcula 
tion Was determined by dividing the molecular Weight of the 
hydrophilic portion of the molecule by the molecular Weight 
of the entire molecule. The division product Was then 
multiplied by 100 to give a percentage, then divided by 5 to 
give an orderly range. For nonionic surfactants, higher HLB 
numbers denote more hydrophilic character. In studies deter 
mining the solubiliZation of various membranes by nonionic 
surfactants, the HLB range from 12.5—14.5 Was determined 
to be the most effective surfactants2. The method of calcu 
lating the HLB numbers Was employed in the comparison of 
N-9, IN-9, Di-IN-9 and their constituent oligomers. 
A normal phase HPLC system has been devised in order 
to isolate the oligomers of N-9 and the iodinated derivatives 
of N-9 for chemical characteriZation. The HPLC separation 
of oligomers Was performed on the Waters system 
(Millipore, Waters Chromatography, Millford, Mass.) that 
included tWo Waters Model 510 pumps, a Waters 740 Data 
Module, a Waters Lambda-Max Model 481 UV detector and 
a Waters Automated Gradient Controller. The process used 
the above HPLC system and a linear gradient solvent system 
from 98% A-2% B to 50% A-50% B over ninety minutes at 
a How rate of 9.9 mL/minute (A=hexane:tetrahydrofuran, 
80:20 v/v; B=2-propanol:Water, 90:10 v/v). A7-pm Zorbax 
NH2 preparative column (21.2><250 mm) (Rockland 
Technologies, Inc.) Was used With the system for the sepa 
ration process. A Waters solvent fraction collector Was 
programmed so that the effluent could be collected every 
sixty seconds betWeen 15 and 80 minutes after the injection 
of the product onto the column. The UV detector Was set at 
280 nm to detect the oligomers therefore alloWing a trace of 
the effluent to be made to determine Which time points 
Would be combined. The solvent of the fractions of interest 
Was evaporated and the oligomer identify determined by 
FAB mass spectrometry. 
A FAB mass spectral analysis alloWed for the identi?ca 
tion of each fraction collected. The fraction believed to be 
the oligomer n=7 Was used to determine the molecular 
Weight for identi?cation purposes. The calculated molecular 
Weight of n=7 for N-9, IN-9 and Di-IN-9 Were 528.7, 654.6 
and 780.5 respectively. After subtraction of the mass of a 
potassium ratio (K’'), the mass spectral analysis revealed 
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molecular Weight values of 528.3, 654.2, and 779.9 for the 
n=7 oligomer of N-9, IN-9 and Di-IN-9 respectively (shown 
in FIGS. 7, 8 and 9). Once identi?ed, the oligomers Were 
characterized by their molecular Weights, HLB values, 
retention times on the normal HPLC system and the log1O of 
their partition coefficients. 
The experimental calculation of the log of the partition 
coefficient values (log P) indicated that iodinated 
nonoxynol-9 Was more lipophilic relative to nonoxynol-9 
(see Table 1). Radiolabeled species ([14C]nonoxynol-9, 
[125I]iodinated nonoxynol-9) Were used to obtain precise 
measurements of the log P values. Iodinated nonoxynol-9 
Was conceptualiZed to be more lipophilic based upon the 
Work by chemists such as Hammett and Hansch. Hammett 
determined that the halogens (F, Cl, Br, I), When attached 
covalently to an aromatic ring, WithdreW a portion of the 
electron density out of the ring. The decrease in electron 
density causes the ring to be less susceptible to induced 
polariZation by solvent molecules, therefore increasing its 
lipophilic character. The hydrophobic parameter at, devel 
oped by Hansch, re?ects a substituent’s ability to impart 
lipophilic character on a molecule (n=log PSubSn-med molecule 
log PunSubSn-med molecule). Hansch found experimentally that 
the halogens created a positive at value in most molecular 
systems Which correlated With an increase in the lipophilic 
ity of the compound. With iodinated nonoxynol-9 possess 
ing greater lipophilic character, the ethylene oxide chain can 
be lengthened to maintain the proper HLB. Additionally, the 
lengthening of the ethylene oxide chain alloWs for reduced 
irritation of the vaginal epithelial lining by reducing the 
formation of micelles. Nonoxynols With larger ethylene 
oxide chains have been shoWn to cause less hemolysis in 
erythrocytes during in vitro irritation studies. Iodide Was 
chosen as the halogen to substitute nonoxynol-9 due to its 
relatively large (I and at values it produces When employed 
as a substituent. With an increase in the hydrophobic 
character, iodinated nonoxynol-9 should insert into sperm 
membranes more readily leading to an increase in spermi 
cidal activity. In addition, the molecular Weight and siZe of 
iodinated nonoxynol-9 is greater than that of nonoxynol-9 
Which leads to the possibility of the molecule being less 
bioavailable from vaginally placed dosage forms. 
At this time, the characteriZation of the oligomers of 
Di-IN-9 has not been completed. The oligomers of interest 
for comparison Were those With 4, 8, 11 and 13 ethylene 
oxide units (n=4, 8, 11, and 13). The oligomer of N-9 (n=8) 
Was chosen since it Was found to be the most abundant 
oligomer in the mixture“. IN-9 (n=13) (HLB=12.83) Was 
selected since its calculated HLB value Was most similar to 
that of N-9 (n=8) (HLB=12.90). The oligomers of n=4 and 
n=11 Were chosen for the characteriZation of a lipophilic 
oligomer and an additional hydrophilic oligomer. The HLB 
values of the entire mixture of oligomers of N-9, IN-9 and 
Di-IN-9 Were calculate using a Weighted computation. 
Using this calculation, IN-9 (n=1—17) (HLB=10.56) and 
Di-IN-9 (n=1—17) (HLB=9.01) Were theoriZed to be more 
lipophilic in character than N-9 (n=1—17) (HLB=12.80). 
Samples of N-9, [14C]N-9, IN-9 and 125IN-9 Were separated 
to compare their chemical and physical characteristics. 
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TABLE 1 
Hydrophilic-lipophilic balance (HLB), chromatographic mobility, and 
partition coefficients of selected oligomers of N-9 versus the 
mono-iodinated nonoxynol-9 (IN-9). 
Nonoxynol-9 (N-9) 
# of E0. Molecular Wt. Rt“ HLBb log PC 
4 398 23.9 I 0.5 9.7 1.6 I 0.05 
8 574 44.2 I 0.7 12.9 1.4 I 0.01 
11 706 60.3 I 0.4 14.2 1.3 I 0.07 
13 794 70.0 I 0.4 14.9 ND" 
Mono-iodinated Nonoxynol-9 (IN-9) 
# of E0. Molecular Wt. Rt“ HLBb log P(1 
4 524 23.5 I 0.4 7.4 2.4 I 0.2 
8 701 43.6 I 0.4 10.5 2.2 I 0.1 
11 833 59.4 I 0.3 12.1 2.2 I 0.1 
13 921 68.5 I 0.3 12.8 1.8 I 0.1 
*[14C]N—9 sample (commercial) contained no N-9 (n = 13) oligomer. 
aHPLC retention time by Zorbax-NH2 preparative column (min, mean : 
S.D., n = 10 for N-9, n = 12 for IN-9). 
bhydrophilic-lipophilic balance (HLB), calculated as the molecular Weight 
of the hydrophilic moiety (polyethylene oxide chain of N-9) divided by 
the molecular Weight of the Whole molecule times 100 and the product is 
further divided by ?ve to have a scale of O-20. (Remington’s Pharmaceu 
tical Sciences, 18th edition, p. 304, 1990) 
Cpartition coe?icient in n-octanol/Water, as determined by [14C]N—9 
dpartition coef?cient in n-octanol/Water, as determined by 1Z5IN-9 
EXAMPLE 4 
Assessment of Spermicidal and Anti-HIV 
Properties 
N-9 and its iodinated derivatives Were assessed in vitro 
for their ability to kill spermatozoa and HIV virions. The 
Sander-Cramer assay Was performed in order to evaluate the 
spermicidal activity of the surfactants and their coprecipi 
tates With PVP. This assay determines the minimum lethal 
dose, reported as a concentration, of spermicide needed to 
kill all spermatoZoa Within tWenty seconds. The folloWing 
oligomers Were incorporated into coprecipitates With PVP 
for the in vitro assessment: IN-9 (n=1—17), IN-9 (n=8) and 
IN-9 (n=13). The neat liquids of N-9 and IN-9 Were also 
assessed for their spermicidal activity. The quantity of active 
compound in each coprecipitate Was determined by a normal 
phase HPLC analysis and presented as a Weight by Weight 
(W/W) percentage. The amount of active compound in each 
coprecipitate Was adjusted by using the W/W percentages so 
that the assays Were conducted using equimolar amounts of 
active compounds. The results of the Sander-Cramer assays 
are shoWn in Table #2. The results indicate that the minimum 
effective concentration (MEC) needed to exhibit complete 
spermicidal activity for the neat liquid of IN-9 (n=1—17) 
(MEC-6.0 pg/mL) is over 30 times less than that needed for 
the neat liquid of N-9 (n=1—17) (MEC=188.0 pg/mL). The 
MEC values indicate that the neat compound IN-9 (n=1—17) 
is 30 times more effective in killing human spermatoZoa than 
the neat compound N-9 (n=1—17) (see Table #2). The 
coprecipitates of IN-9 (n=8) (MEC=94 pg/mL) and IN-9 
(n=13) (MEC=23 pg/mL) presented signi?cantly different 
spermicidal potencies When compared to N-9 (n=1—17), 
suggesting that isolation of a single oligomer may be a 
feasible route to increase spermicidal action While decreas 
ing irritation potential. 
The compounds used in the Sander-Cramer assays (neat 
liquids and coprecipitates) Were evaluated for their anti-HIV 
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activity using the Cell-Free and Cell-Associated Inactivation 
Assays (see Table #3). Both assays employ solutions of 
active compound at varying concentrations in order to detect 
the optimal concentration to reduce the infectivity of a 
redetermined HIV viral load in the form of free HIV-1-RF or 5 
RF infected H9 cells. A solution of active compound is 
determined to have sufficient anti-viral activity if, When 
tested, a viral titer reduction of at least tWo log1, units 
occurs. N-9 and IN-9, in their neat liquid forms, Were both 10 
found to be virucidal against cell-free and cell-associate 
HIV. It Was determined that IN-9 (n=1—17) is at least as 
effective in killing HIV as N-9 (n=1—17) (see Table #3). 
Furthermore, IN-9 appears to be slightly more effective than 
N-9 against cell-associated HIV Which appears to be the 
predominant form of HIV in male to female transmission via 
sexual intercourse. The coprecipitates of N-9 (n=1—17) and 
IN-9 (n=1—17) Were also virucidal in both assays. 
TABLE 2 
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Acosta, Anibal A. and Kruger, Thinus F. (eds.) Human 
Spermatozoa in Assisted Reproduction, pp. 172—192. 
(NeW York: The Parthenon Publishing Group). 
. Helenius, Ari and Simons, Kai (1975). solubiliZation of 
Membranes by Detergents, Biochimica et Biophysica 
Acta, 415, pp. 29—79. (Amsterdam: Elsevier Publishing 
Company). 
. Shachat, Norman and GreenWald, Harold L. (1967). 
Mechanism of Ethylene Oxide Condensation. Schick, 
Martin J. (ed.) N0ni0nic Surfactants, pp. 8—42. (NeW 
York: Marcel Dekker, Inc.). 
. Walter, Brian A. and Digenis, George A. (1991). High 
Performance Liquid Chromatographic (HPLC) Analysis 
of Oligomeric Components of the Spermicide 
Nonoxynol-9. Pharmaceutical Research, 8, pp. 409—411. 
. Walter, Brian A., HaWi, Amale A., Zavos, Panayiotis M., 
and Digenis, George A. (1991). SolubiliZation and in 
Vitro Spermicidal Assessment of Nonoxynol-9 and 
Selected Fractions Using Rabbit SpermatoZoa. Pharma 
ceutical Research, 8, pp. 403—408. 
Spermicidal Activity Results 
Sander-Cramer Assay 
Highest 
N-9 Spermicidal 
Initial Conc. Equimolar Dilution, M.E.C. 
Compound Solvent (‘ug/mL) (‘ug/mL) median (‘ug/mL) n Solubility 
N-9 (1-17) dH2O 24 24 128.0 188.0 17 OK clear soln. ph 6.5, 7.0# 
IN-9 (1-17) dH2O 29 24 4096.0 6.0 17 OK hazy soln. pH 7.0, 7.5 
IN-9 (1—17)/PVP dH2O 386 24 2048.0 12.0 17 OK haZy soln. pH 5.0, 5.0 
IN-9 (8)/PVP dH2O 545 24 256.0 94.0 17 OK hazy soln. pH 5.5, 5.5 
IN-9 (13)/PVP dH2O 555 24 1024.0 23.0 17 OK cloudy soln. pH 5.0, 5.5 
N-9 (1—17)* dH2O 24 24 128.0 188.0 17 OK clear soln. pH 6.5, 6.5 
PVP dH2O 100 0 FAILED N/A 3 OK 
*Commercial control; #TWo pH determinations 
N-9 = Nonoxynol-9; IN-9 = Mono-iodinated nonoxynol-9; PVP = Polyvinylpyrrolidone; M.E.C. = Minimum effective concentration; 
Conc. = Concentration; Soln. = Solution; n = Number of determinations 
TABLE 3 
Anti-HIV Activity Assessment in Cell-Free and Cell-Associated Viral Inactivation Assays 
Cell-Free HIV Inactivation Cell-Associated HIV Inactivation 
Compound Solvent Date Conc. (%) Infec. Red. (log)* Date Conc. (%) Infec. Red. (log)* 
N-9 (1-17) dH2O 02/25/98 0.1 >3.5 04/16/98 0.1 3.2 
0.032 >4.5 0.032 2.5 
0.01 2.3 0.01 0.8 
0.0032 0.3 0.0032 0.8 
IN-9 (1-17) dH2O 02/25/98 0.1 >4.5 04/16/98 0.1 >5.0 
0.032 3.3 0.032 2.3 
0.01 2.3 0.01 1.8 
0.0032 0.3 0.0032 1.0 
Positive Control dH2O 02/25/98 0.1 >3.5 04/16/98 0.1 >5.0 
0.032 4.3 0.032 1.7 
0.01 1.5 0.01 1.0 
0.0032 0.0 0.0032 0.7 
*Indicates reduction of infectious viral titer of HIV-1-CF stock after a tWo minute incubation With the compound (reported in log 
units). 
Only the preferred embodiment of the present invention and an example of its versatility are shoWn and described in the present disclo 
sure. It is to be understood that the present invention is capable of use in various other combinations and environments and is capable 
of changes or modi?cations Within the scope of the inventive concept as expressed herein. 
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What is claimed is: 
1. A compound of the formula: 
Wherein R is a carbon atom containing moiety having at least 
6 carbon atoms, Q is I, and n=1—25. 
2. The compound according to claim 1, Wherein n=8. 
3. The compound according to claim 1, Wherein n=9. 
4. The compound according to claim 1, Wherein n is from 
4 to 15. 
5. The compound according to claim 4, Wherein n is 6—8. 
6. The compound according to claim 5, Wherein n=6. 
7. The compound according to claim 1, Wherein n=7. 
8. The compound according to claim 1, Which is Water 
soluble. 
9. The compound according to claim 1, Which is Water 
insoluble. 
10. The compound according to claim 1, Wherein one or 
both iodine atoms are radioisotopes, and the iodine radio 
isotopes are selected from the group consisting of 123 
iodine, 125-iodine and 131-iodine. 
11. The compound according to claim 1, Wherein R is 
nonyl or octyl. 
12. Apharmaceutical composition comprising an effective 
amount of a compound of the formula: 
14 
0 Wherein R is a carbon atom containing moiety having at least 
6 carbon atoms, Q is I, and n=1—25, and a pharmaceutically 
acceptable carrier. 
13. The composition according to claim 12, in a form 
suitable for oral administration selected from the group 
consisting of tablets, loZenges, granules, dragees, capsules, 
and pills. 
14. The composition according to claim 12, further com 
prising polyvinylpyrrolidone (PVP). 
15. The composition according to claim 12, in a form 
suitable for vaginal application. 
16. The composition according to claim 15, in a form 
selected from the group consisting of a sponge, cream, 
liquid, douche, gel, jelly, aerosol foam, impregnated tampon, 
a controlled delivery device, and a lubricant on a condom or 
a cap diaphragm. 
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17. Aprocess for preparing a compound of claim 1 of the 
formula: 
30 
I 
35 R O—(-CH2CH2O j,,—H 
Q 
40 Wherein R is a carbon atom containing moiety having at least 
6 carbon atoms, Q is I, and n=1—25, comprising the steps of: 
(a) reacting thallium tri?uoroacetate With a compound of 
formula: 
Wherein Q and n are as de?ned above to form an electro 
philic thallium intermediate, 
45 
(b) iodinating the intermediate to form a monoiodinated 
intermediate in the ortho-position; 
55 (c) then further reacting With additional thallium tri?uo 
racetate to form a monoiodinated electrophilic thallium 
intermediate; and 
(d) reacting the intermediate With additional iodonatino 
6O reactant to form a compound of claim 1. 
18. The process of claim 17, further comprising: 
isolating at least one iodinated oligomer. 
* * * * * 
